PCRX Stockholders Should Contact Shareholder Rights Firm Robbins For Information About The Class Action Against Pacira Biosciences, Inc.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance ...
sambadenglish11h
IAS officer Satyabrata Rout appointed as Odisha Assembly Secretary
IAS officer Satyabrata Rout has been appointed as the Secretary of Odisha Legislative Assembly. The General Administration ...
PCRX Stockholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm ...
devdiscourse1d
Historic Budget Session in Jammu & Kashmir Assembly: A New Era Begins
The Jammu and Kashmir Assembly's budget session commences on March 3 under the new National Conference government led by Omar ...
Kashmir Life1d
LG Summons Jammu Kashmir Assembly on March 3 for First NC-Led Govt Budget Session
Lieutenant Governor Manoj Sinha has summoned the Jammu & Kashmir Assembly from March 3 for the first budget presentation by ...
Pharmabiz1d
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma
Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
Le Lézard1d
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. . Shareholders who purchased shares ...
Targeted Oncology2d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...
Fintel on MSN8d
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation
Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...